Kane Biotech Inc. KNE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -70.79% | -89.04% | -116.91% | -99.34% | -95.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.79% | -89.04% | -116.91% | -99.34% | -95.54% |
| Cost of Revenue | -90.96% | -86.70% | -113.53% | -98.13% | -72.05% |
| Gross Profit | 103.04% | -109.46% | 108.67% | -100.90% | -112.49% |
| SG&A Expenses | 380.59% | -48.87% | 60.80% | -62.00% | -85.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.15% | -52.36% | -35.10% | -71.15% | -82.59% |
| Operating Income | -184.68% | 39.33% | 22.49% | 11.96% | 75.30% |
| Income Before Tax | -137.99% | 38.99% | 39.28% | 11.37% | 71.66% |
| Income Tax Expenses | -- | -- | 91.72% | -- | -- |
| Earnings from Continuing Operations | -139.10% | 38.62% | -341.56% | 11.37% | 71.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -139.10% | 38.62% | 49.29% | 0.72% | -103.75% |
| EBIT | -184.68% | 39.33% | 22.49% | 11.96% | 75.30% |
| EBITDA | -236.53% | 38.51% | 21.20% | 21.83% | 78.39% |
| EPS Basic | -350.00% | 58.57% | 70.27% | 58.06% | -103.15% |
| Normalized Basic EPS | -309.09% | 59.09% | 56.76% | 63.64% | 73.81% |
| EPS Diluted | -350.00% | 58.57% | -7.69% | 81.43% | -103.91% |
| Normalized Diluted EPS | -309.09% | 59.09% | 56.76% | 63.64% | 68.57% |
| Average Basic Shares Outstanding | -46.80% | 49.25% | 73.33% | 136.15% | 18.39% |
| Average Diluted Shares Outstanding | -46.80% | 49.25% | 73.33% | 136.15% | -0.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |